Latest news about Parnax Lab
Parnax Lab
123.86
-4.87(-3.78%)
Company Performance:
View Company Insights1D-3.78%
1M-3.08%
6M+3.52%
1Y+3.52%
5Y+3.52%
More news about Parnax Lab
27Jun 26
Parnax Lab promoter acquires 3.15% stake via inter-se gift transfer
Prakash Mahasukhlal Shah, a promoter of Parnax Lab Limited, proposed acquiring 3,61,872 equity shares from Ila B. Shah via inter-se gift transfer. The transaction, exempt from open offer regulations, will increase Shah's holding to 13.61% while reducing Ila B. Shah's to 8.71%, leaving the total promoter group holding unchanged at 22.32%.
28May 26
Parnax Lab reports FY26 net profit of ₹1,177.68 lakh
Parnax Lab Limited reported a consolidated net profit of ₹1,177.68 lakh for FY26, up from ₹1,151.90 lakh in FY25, with total revenue rising to ₹25,232.56 lakh. The board approved the audited financial results and the re-appointment of Mr. Yogesh K. Varia as an Independent Director.
20May 26
Parnax Lab board meets May 28 to consider Q4, FY26 results
Parnax Lab Limited will hold a board meeting on May 28, 2026, to approve audited financial results for Q4 and FY26. The trading window is closed from April 1, 2026, and will reopen 48 hours post-results.
08Apr 26
Parnax Lab Ltd. Submits Quarterly Compliance Certificate for Q4 FY26 to BSE
Parnax Lab Ltd. filed its Q4 FY26 compliance certificate with BSE on April 8, 2026, confirming no dematerialization requests were received during the quarter ended March 31, 2026. The filing, made under SEBI Regulation 74(5), was verified by registrar MUFG Intime India Private Limited and signed by Company Secretary Preet Kukreja, demonstrating adherence to mandatory quarterly compliance requirements.
15Feb 26
Parnax Lab Limited Reports Strong Q3FY26 Results with 56.45% Revenue Growth
Parnax Lab Limited announced robust Q3FY26 financial results with consolidated revenue from operations reaching ₹6,294.15 lakhs, marking a 56.45% year-on-year growth. The company's consolidated net profit surged 124.29% to ₹271.47 lakhs, while standalone operations showed even stronger growth with revenue increasing 174.58% to ₹270.82 lakhs and net profit jumping 349.43% to ₹70.91 lakhs.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Zydus Life Science
Cipla
Laurus Labs
Mankind Pharma
Dr Reddys Laboratories
Aurobindo Pharma
Lupin
1,849.90
(-0.81%)
9,602.00
(-0.23%)
4,928.50
(-1.13%)
1,180.30
(+0.87%)
1,399.00
(+1.16%)
2,026.20
(-0.38%)
2,500.00
(+1.42%)
1,200.40
(-0.89%)
1,716.00
(-0.32%)
2,100.70
(-0.10%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
